Dexcom to launch G7 15 Day CGM next month

Dexcom (NSDQ:DXCM) announced today that it plans to launch its G7 15 Day continuous glucose monitor (CGM) in the U.S. next month.

The San Diego–based company plans to make the CGM available for people over the age of 18 with diabetes on Dec. 1. Initially, the company plans to make the sensor available for users who receive their CGMs through durable medical equipment (DME) providers.

Dexcom — one of the largest diabetes tech companies in the world — said the CGM also has coverage for Medicare beneficiaries, meeting the category requirements for therapeutic CGM systems set forth by CMS.

At launch, the CGM pairs with the iLet Bionic Pancreas from Beta Bionics and the Omnipod 5 from Insulet. The company says it has work underway with Tandem Diabetes Care to finalize integration G7 15 Day with its pumps as well. Yesterday, the company also announced that the G7 15 Day works with Smart Basal, its new CGM-integrated basal insulin dosing optimizer.

Read more about Dexcom and the rest of the diabetes tech industry in our free Diabetes Technology Special Report.

Visit here to purchase our Medtech Market Special Report on CGMs.

G7 15 Day received FDA clearance for people over the age of 18 years old in the U.S. in April. Clearance made the G7, Dexcom’s latest-generation CGM, the longest-lasting wearable CGM, according to the company. The offering delivers several features of the existing G7 platform. That includes a waterproof sensor, connectivity to the Apple Watch, plus automated activity, simplified meal and new medication logging. Its 12-hour grace period allows a seamless transition when replacing sensors as well.

New features include the longer wear, reaching up to 15.5 days, plus a mean absolute relative difference (MARD, a measure of CGM accuracy) of 8%. It also offers easier glucose management with fewer monthly sensor changes and reduced waste.

“We’ve heard loud and clear from our users — they want more time with the Dexcom G7 because it gives them confidence, clarity, and control over their health,” said Grant Ovzinsky, VP of Product Management at Dexcom. “With 15.5 days* of wear, we’re delivering on that ask. Fewer sensor changes mean less disruption, and more time benefiting from the most accurate CGM. It’s a meaningful step forward in empowering people with diabetes to live life on their terms.”